After reading the 10-k initial study site activation is currently underway in the U.S and Australia, with (PhII) initiation expected in Aug.
As for RP2 the company had received queries from the FDA (Feb) and the MHRA (May) in response to the submission of pre-IND questions. Responses delayed the intended opening of it. The trial is now expected to initiate, initially in the U.K., and Opdivo will also be used.